Lege Artis Medicinae

[Fulvestrant treatment of breast cancer in a patient with severe comorbidities - a case report]

BÁNHEGYI Róbert János1, NAGY Ágnes Krisztina1, LIPPAI Zsuzsanna1, FÜLÖP Ferenc2, RAJTÁR Mária3, PIKÓ Béla1

MAY 20, 2017

Lege Artis Medicinae - 2017;27(04-05)

[Today, despite the increasing number of targeted and immunotherapeutic agents in oncology, the endocrine therapy is still an effective and manageable modality with acceptable safety profile in the treatment of hormone receptor positive breast cancer, especially in patients with multiple severe comorbidities. We present a case of successful treatment with fulvestrant of a woman with breast cancer and non-Hodgkin lymphoma, diabetes and heart failure, that emphasizes the need of personalized treatment. ]

AFFILIATIONS

  1. Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Megyei Onkológiai Központ
  2. Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház Radiológiai Osztály
  3. Bács-Kiskun Megyei Kórház, Nukleáris Medicina Osztály

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Vigilance for Drug Safety: the SCOPE Project – An Interview with Mick Foy, Pharmacovigilance Working Group Leader of the British Medicines Authority (MHRA) ]

CZIGLÉNYI Boglárka

Lege Artis Medicinae

[The Anatomic Theater – The Publicity of the Opened Body ]

CZIGLÉNYI Boglárka

Lege Artis Medicinae

[Deadly Caress, or the Apotheosis of Cosmic Pain ]

GEREVICH József

Lege Artis Medicinae

[The World and I are One – On the Photographs of Rinko Kawauchi ]

FARKAS Renáta

Lege Artis Medicinae

[Mazes and compass in prognostic value of cardiovascular risk factors]

KÉKES Ede, KISS István

[The risk assessment of cardiovascular disease is dispensable in everyday practice, because this disease-group gives the high-est death rates all over the world - in developed countries, in Central European Region, including Hungary. Based on reliable surveys world side, we need in addition to coronary heart disease, stroke has been reckoned today to peripheral vascular disease, type-2 diabetes, and chronic kidney diseases as well. It seems useful to the new name i.e., atherosclerotic cardiovascular diseases. It stands as smoking, hypertension, dyslipidemia risk factors among this group of diseases in the background, but more and more importance is given to visceral obesity, physical inactivity, alcohol consumption and psycho-social status. It has to count with the fact that the individual factors together and appear further worsen to mortality rate. The greatest interference arises because the cardiovascular risk estimation proposed by embodiments of non-uniform principles. Undoubtedly, the resolution of ACC/AHA 2010 was the first correct compass, because the classification and utility values of the factors precisely regulated. But in addition, it is essential that in the risk assessment not only the “global estimation” (tables, other forms) will be conducted, but also other important parameters characterizing the extended factors (vascular structure, obesity, psycho-social status, etc.) - set schedule and regulations - acting on to be carried out. We presented in cardiovascular risk assessment methodology and the most profitable methods of estimation based on the preventive guidelines, extern opinions generally accepted now and own experiences. We propose to modify the risk assessment me-thod.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Effective fulvestrant treatment of indolent breast cancer in a patient with low compliance - a case report]

HÓDI Veronika

[In the explosive development of treatment of oncological patients, there are still patients who are not always cooperative even in their own treatment. The case report exemplifies that even in this case the endocrine treatment has its place in the hormone receptor positive breast cancer. ]

Lege Artis Medicinae

[Long survival with multimodal therapy]

MÉSZÁROS Edina, LANDHERR László

[Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death in women worldwide. Approxi­mately two-thirds of cases are potencially sensitive to endocrine therapy. Fulvestrant is a selective estrogen receptor downregulator indicated for the treatment of postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antiestrogen therapy, or disease progression on therapy with antiestrogen. We are reporting here a nearly ten-years-long sucessful combination of multiple treatment lines of anti-estrogen treatment, chemotherapy and radiotherapy in a case of a patient with hormone receptor positive, HER2 negative breast cancer with pulmonary metastases.]

Lege Artis Medicinae

[PSORIASIS TODAY]

SZEGEDI Andrea, KISS Flóra, GAÁL János

[Psoriasis is one of the most common dermatological disorders. It is an immune-mediated chronic inflammatory disease that primarily affects the skin and the joints, and substantially reduces the quality of life. It occurs worldwide, with a prevalence of about 2% in developed countries. Today numerous studies are continuously published on psoriasis. Important progress has been made especially on its genetics, pathomechanism and comorbidity. In the past few years, several efficient therapeutic approaches have been developed and applied. With the appearance of biological therapies, the inflammatory process can be targeted more selectively than before. The paper reviews most recent data on the pathogenesis, immunological background, comorbidity and reduced quality of life associated with psoriasis, and presents therapeutic approaches with special focus on recent advances. The increased knowledge allows of a more efficient treatment and care of patients with proriasis, thus significantly increasing their quality of life.]

Clinical Neuroscience

The effect of psychiatric comorbidities and stress-coping strategies on perceived quality of life in migraine

PETROVICS-BALOG Anna, MAJLÁTH Zsófia, LUKÁCS Melinda, HOLCZER Adrienn, MUST Anita, TAJTI János, VÉCSEI László

Purpose – Migraine is one of the most disabling primary headache conditions. We aimed to detect hidden symptoms of anxiety and depression and to survey stress-coping mechanisms and related quality of life in a large migraine population without any known psychiatric comorbidity. Method – 123 migraine patients (MG) and 66 healthy subjects (HC) completed the Beck Depression Inventory-II (BDI-II), the State and Trait Anxiety Inventory (S-STAI and T-STAI), the Stress and Coping Inventory (SCI) and the 36-Item Short Form Health Survey (SF-36). Results – MG patients reached significantly higher scores on the BDI-II and the T-STAI yielding previously undetected anxiety and depression symptoms. Significant differences were present on the SCI: higher stress scores and lower coping levels suggested impaired stress-coping strategies in migraine. MG patients achieved significantly lower scores on most of SF-36 subscales indicating lower perceived quality of life. Significant correlations were found between BDI-II, T-STAI, SCI scores and subscales of the SF-36. Conclusion – Unrecognized symptoms of anxiety and depression, as well as less effective stress-coping strategies might be related to the lower perceived quality of life in migraine. The screening of these symptoms might lead to more focused and efficient therapeutic strategies. Addressing stress management techniques could improve quality of life on the long-term.

Lege Artis Medicinae

[Treating breast cancer patients with fulvestrant - could it be more efficacious?]

NAGY Zsuzsanna

[Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40%. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.]